Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Open Orphan Plc ( (GB:HVO) ).
hVIVO has signed a contract with ILiAD Biotechnologies to run the world’s first pivotal Phase III human challenge trial of a whooping cough vaccine, testing ILiAD’s intranasal candidate BPZE1 against the current Tdap standard. The study, expected to enrol more than 500 volunteers via FluCamp, will be hVIVO’s largest human challenge trial to date and will be supported by the company’s bacterial laboratory in Canary Wharf.
Revenues from the multi‑year contract are expected to start in the first half of 2026, with most recognised in 2026 and 2027, providing a significant boost to near‑ and mid‑term income. Management said the deal underscores growing regulatory acceptance of human challenge trials as a faster route to pivotal efficacy data, potentially strengthening hVIVO’s industry position while accelerating development of vaccines for diseases with unpredictable epidemiology such as whooping cough.
The most recent analyst rating on (GB:HVO) stock is a Buy with a £10.00 price target. To see the full list of analyst forecasts on Open Orphan Plc stock, see the GB:HVO Stock Forecast page.
Spark’s Take on HVO Stock
According to Spark, TipRanks’ AI Analyst, HVO is a Neutral.
The score is held back primarily by weakened financial performance (losses and significant cash burn) and liquidity/visibility concerns highlighted on the earnings call (cash depletion and a lower, restated order book). Technicals are supportive with an uptrend, but overbought readings temper the signal, while valuation remains challenged due to negative earnings and the dividend suspension.
To see Spark’s full report on HVO stock, click here.
More about Open Orphan Plc
hVIVO plc is a purpose-built, full-service international clinical development partner and the global leader in human challenge trials, working with seven of the world’s ten largest biopharma companies. The group offers an end-to-end platform from preclinical strategy through Phase II trials and specialist lab services, leveraging owned sites, laboratories and its FluCamp recruitment arm across the UK and Germany.
Average Trading Volume: 3,535,868
Technical Sentiment Signal: Sell
Current Market Cap: £64.37M
Learn more about HVO stock on TipRanks’ Stock Analysis page.